Background:SOD1 mutations are the most common cause of amyotrophic lateral sclerosis(ALS)in non-Caucasian patients.Detailed natural history profiles of SOD1-mutant patients will be beneficial for the strategy and inte...Background:SOD1 mutations are the most common cause of amyotrophic lateral sclerosis(ALS)in non-Caucasian patients.Detailed natural history profiles of SOD1-mutant patients will be beneficial for the strategy and interpretation of future SOD1-targeted clinical practice.Methods:Mutational distribution,age at onset(AAO),site of onset,diagnostic delay,disease progression(rate of ALSFRS-R decrease,ΔFS)and survival were analysed.Further comparisons between heredity of disease,gender,and mutations were performed.Results:Sixty-six cases with 43 SOD1 mutations were included and analysed,with p.His47Arg as the leading mutation and seven novel variants identified.The mean(SD)AAO was 43.92 years(9.24)for all subjects,with a significant difference between patients carrying mutations in exon 2(n=24,46.83,8.31)and exon 4(n=18,37.75,7.67)(p=0.002).The median(IQR)diagnostic delay from symptom onset was 14.50(6.00–36.50)months for all SOD1-mutant patients,9.50(4.75–24.25)months for males and 24.00(9.50–47.50)months for females,revealing a gender difference(p=0.009).Similar advantages in median(IQR)ΔFS[male:female,0.55(0.24–0.94)vs 0.19(0.06–0.90),p=0.041]and mean(95%CI)survival[57.4(38.90–75.90)months vs 125.6(99.80–151.50)months,p=0.006]were also observed in females,both of which existed in sporadic ALS only when stratified by familiar or sporadic ALS.Conclusions:The results highlight a distinct mutational distribution and natural history spectrum in ALS patients carrying SOD1 mutations in China.A prominent mild disease progression was observed in female patients,which had rarely been reported in the previous literature.This finding,together with the detailed analysis of natural history among each mutation,can have important implications for future genetic counselling and SOD1-targeted clinical trials.展开更多
基金This work was supported by the National Natural Science Foundation of China under Grant 81030019Peking University-Ulm University Union Foundation under Grant PKU2017ZC001-2+1 种基金the Natural Science Foundation of Beijing Municipality under Grant 7102161the National Clinical Key Program of China.
文摘Background:SOD1 mutations are the most common cause of amyotrophic lateral sclerosis(ALS)in non-Caucasian patients.Detailed natural history profiles of SOD1-mutant patients will be beneficial for the strategy and interpretation of future SOD1-targeted clinical practice.Methods:Mutational distribution,age at onset(AAO),site of onset,diagnostic delay,disease progression(rate of ALSFRS-R decrease,ΔFS)and survival were analysed.Further comparisons between heredity of disease,gender,and mutations were performed.Results:Sixty-six cases with 43 SOD1 mutations were included and analysed,with p.His47Arg as the leading mutation and seven novel variants identified.The mean(SD)AAO was 43.92 years(9.24)for all subjects,with a significant difference between patients carrying mutations in exon 2(n=24,46.83,8.31)and exon 4(n=18,37.75,7.67)(p=0.002).The median(IQR)diagnostic delay from symptom onset was 14.50(6.00–36.50)months for all SOD1-mutant patients,9.50(4.75–24.25)months for males and 24.00(9.50–47.50)months for females,revealing a gender difference(p=0.009).Similar advantages in median(IQR)ΔFS[male:female,0.55(0.24–0.94)vs 0.19(0.06–0.90),p=0.041]and mean(95%CI)survival[57.4(38.90–75.90)months vs 125.6(99.80–151.50)months,p=0.006]were also observed in females,both of which existed in sporadic ALS only when stratified by familiar or sporadic ALS.Conclusions:The results highlight a distinct mutational distribution and natural history spectrum in ALS patients carrying SOD1 mutations in China.A prominent mild disease progression was observed in female patients,which had rarely been reported in the previous literature.This finding,together with the detailed analysis of natural history among each mutation,can have important implications for future genetic counselling and SOD1-targeted clinical trials.
